Skip to content

Viridian Therapeutics

US · VRDN #2731 by market cap Listed 1970
29.96 -1.48 -4.71%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43
    Market Newswire · 2026/8/5
  • Rating change
    Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/7/1
  • Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $34
    Market Newswire · 2026/11/6
  • Rating change
    RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
    Market Newswire · 2026/10/9
  • Rating change
    Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $39
    Market Newswire · 2026/8/13
  • Rating change
    Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31
    Market Newswire · 2026/10/14
  • Rating change
    Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26
    Market Newswire · 2026/10/31
  • Rating change
    LifeSci Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $35
    Market Newswire · 2026/10/3
  • Rating change
    RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $38
    Market Newswire · 2026/9/22
  • H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/11/10
  • Rating change
    Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/8/14
  • A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $33 to $42
    Market Newswire · 2026/11/6
  • Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/11/10
  • A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $40 to $53
    Market Newswire · 2026/11/5
  • Rating change
    Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $40
    Market Newswire · 2026/8/20
  • Rating change
    Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
    Market Newswire · 2026/9/1
  • Rating change
    A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41
    Market Newswire · 2026/8/7
  • Rating change
    Jefferies Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/6/30
  • Rating change
    Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $39
    Market Newswire · 2026/8/7
  • Rating change
    Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $41
    Market Newswire · 2026/11/4
  • Rating change
    A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $43
    Market Newswire · 2026/6/30
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Fortrea Holdings Inc. (FTRE)
    TipRanks · 2026/6/29
  • Rating change
    A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $35
    Market Newswire · 2026/6/29
  • Rating change
    Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Maintains Target Price $20
    Market Newswire · 2026/6/17
  • Rating change
    Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $32
    Market Newswire · 2026/6/28

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Viridian Therapeutics discussion 0 comments

Add a comment